Study to Assess SLN124 in Patients With Polycythemia Vera

Polycythemia vera

Washington University School of Medicine – Polycythemia vera Novartis Pharmaceuticals – Polycythemia vera

Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera Study to Assess SLN124 in Patients With Polycythemia Vera A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea. Effect of Phlebotomy on Heartrate in Polycythemia Patients MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms Safety Evaluation Study for Patients With Polycythemia Vera Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit Extension Study After Completion of Phase 2 Study for P1101 With Polycythemia Vera (PV) Patients (Study A19-201) Ruxolitinib in Thrombocythemia and Polycythemia Vera To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy. Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders Ruxolitinib and Daunorubicin (CPX-351) in Treating Patients With Secondary Acute Myeloid Leukemia Transformed From Myeloproliferative Neoplasms Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients Correlative Biomarker Study in Patients With Myeloproliferative Disorders 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms PD-1 Inhibition in Advanced Myeloproliferative Neoplasms Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms A Study in Myeloproliferative Disorders Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia Myeloproliferative Neoplasms and Bone Structure A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation Myeloproliferative Neoplasms: an In-depth Case-control Study Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders Familial Myeloproliferative Disorders A Safety Study of XL019 in Adults With Myelofibrosis Dual Vaccine Trial in Myeloproliferative Neoplasms Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms Myeloproliferative Neoplastic Diseases Observatory From Brest Research Tissue Bank Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis Pomalidomide for Myelofibrosis Patients Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis Tissue Banking Study – Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV) Effects of Imatinib Mesylate in Polycythemia Vera Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure Natural Killer Cells and Polycythemia Vera (Vaquez’s Disease) Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes Dasatinib in Polycythemia Vera Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera Hepcidin Mimetic in Patients With Polycythemia Vera Clopidogrel and Aspirin for the Treatment of Polycythemia Vera A Phase 1 Study of XL019 in Adults With Polycythemia Vera Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study